SCHEMBL21552853

SCHEMBL21552853

CCOC(=O)CCc1cn(-c2ccc(F)cc2)c(=O)c(N2CCN(C(=O)O)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 2/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552943 0.90 KDM4E (0.43) GABRA2GABRB2KDM4EPOLBTSHR
SCHEMBL21564780 0.89 GABRA2 (0.43) GABRA2GABRB2KDM4EPOLBTSHR
SCHEMBL21564861 0.88 GRIA1 (0.41) GABRA2GABRB2KDM4EPOLBTSHR
SCHEMBL21564616 0.87 POLB (0.43) GABRA2GABRB2KDM4EPOLBTSHR
SCHEMBL21553119 0.86 HTR3E (0.36) KDM4EPOLBALDH1A1MEN1KMT2A
SCHEMBL21553067 0.86 DDX3X (0.37) KDM4EALDH1A1CYP3A4MEN1KMT2A
SCHEMBL21552906 0.86 L3MBTL1 (0.41) KDM4ETSHRALDH1A1MEN1KMT2A
SCHEMBL21553098 0.83 GFER (0.38) KDM4EPOLBTSHRALDH1A1MEN1
SCHEMBL21553057 0.82 LMNA (0.38) KDM4EPOLBTSHRALDH1A1MEN1
SCHEMBL21553086 0.81 GABRA2 (0.39) GABRA2GABRB2KDM4EPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A GABRA2 1726/4885GABRB2 1280/4885KDM4E 18/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A GABRA2 1726/4885GABRB2 1280/4885KDM4E 18/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A GABRA2 1845/4885GABRB2 1428/4885KDM4E 18/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A GABRA2 1726/4885GABRB2 1280/4885KDM4E 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.